Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
AssigneeRepros Therapeutics Inc.
InventorsJoseph S. Podolski, Ronald D. Wiehle
Life of this patent
Estimating the term…
Abstract
The present invention relates to the long-term administration of a selective estrogen receptor modulator (SERM) with a short half-life for the treatment of a variety of estrogen receptor-mediated conditions. The SERM may be administered at a concentration at or below that of a SERM with a long half-life in order to achieve an equivalent therapeutic effect.
Claims19
A method for treating an estrogen receptor-mediated condition comprising administering a selective estrogen receptor modulator (SERM) or a pharmaceutically acceptable salt thereof selected from the group consisting of droloxifene, levormeloxifene, (Deaminohydroxy)toremifene, raloxifene, bazedoxifene and arzoxifene for a period of at least 6 months at a dosage of between 1 and 19 mg per day or every other day to a patient in need of such treatment.
(canceled)
(canceled)
(canceled)
(canceled)
18-24. (canceled)
Dependencies are inferred from the claim text.